Our Testimonials
See what our customers have siad about the research papers that we have provided.
| Testimonials |
|---|
| "Dr. Cheryl Barton of Pharmavision recently presented at a global management conference for West. Our goal was to understand how the many advances across the broad vaccine spectrum would impact our core injectable business as well as our future innovation plans. We shared our base understanding of the vaccine market and our long range growth platforms with Dr. Barton and her team at Pharmavision and they crafted a very insightful overview of the industry highlighting key areas of interest. The result was an outstanding interactive presentation. Feedback across West has been very positive and has led to additional research opportunities between West and Pharmavision. Glen Zimmermann Manager, Strategic Marketing Initiatives West Pharmaceutical Services 101 Gordon Drive, Lionville PA 19341 USA"
West Pharmaceutical Services
|
| "Espicom Business Intelligence has enjoyed a successful and much valued collaborative relationship with Dr. Cheryl Barton since 2004. Working together on a variety of projects covering the CNS, Oncology and Drug Delivery sectors has resulted in the launch of a highly acclaimed series of market intelligence reports which offer a fresh and independent perspective through proprietary analysis and sales forecasts. Ian Taylor, Research Director, Espicom Business Intelligence City Fields Business Park, Chichester, PO20 2FS, United Kingdom "
Espicom Business Intelligence
|
| "“Pharmavision have provided us with high quality, commercially valuable and timely analysis for several years as research partners for Business Insights. We have always been impressed by their professionalism and diligence in providing bespoke research and analysis services.” Gaurav Misra Business Insights Head of Healthcare Analysis London "
Business Insights
|
| "Forbes Volume 6 / Number 12 / December 2007 Technology Trends to Watch in 2008 Reverse genetics Interest in personalized medicine hasn't been lost on incumbent biotech giants, like Roche,Abbott Laboratories [ABT] and Siemens AG [SI]. Many of them are launching initiatives that combine in vitro diagnostics with therapeutic solutions in one procedure, according to Dr Cheryl Barton, founder of U.K. consultant firm PharmaVision. Targeted carrier systems represented about half of the $6.5 billion market for advanced drug delivery in 2006, reported Barton. By 2015, the sector could see nearly thirty new commercial therapies focusing on treatment for cancer, cardiovascular and infectious disease. "
Forbes/Wolfe Emerging Tech Report
|
| "Locking up the IP Dendritic Nanotechnologies' Donald Tomalia is one of the pioneers of the dendrimer field. Together with the University of Michigan's James Baker, he controls most of the IP behind dendrimers. In 1992, Tomalia left Dow Chemical to found Midland, Michigan–based Dendritech. Nine years later, when Dendritech folded, Dow granted Tomalia global licensing rights to dendrimer applications in return for waiving future royalty rights; this created the basis for another Tomalia startup, Dendritic Sciences of Mount Pleasant, Michigan. Two years later, Starpharma got together with Tomalia to form a joint venture, Dendritic Nanotechnologies, headquartered in Melbourne, Australia with production and laboratories in Central Michigan University's Center for Applied Research and Technology in Mount Pleasant. From 1985 to 1995, Dow Chemical and Stamford, Connecticut–based Xerox were dominant dendrimer patent holders, the latter patenting the use of dendrimers in toner and ink dispersion; Bayer and DSM of Heerlen, The Netherlands, also were granted patents for the use of dendrimers in plastics manufacturing and other nano-based products. In 2005, Dow Chemical assigned its entire dendrimer IP to Dendritic Nanotechnologies in exchange for an equity stake in the firm. Then, a year later, Starpharma acquired Dendritic Nanotechnologies for $6.97 million in shares. Thus, Starpharma is currently the dominant dendrimer patent holder. "I believe they have up to 90% of the patents," says analyst/consultant Cheryl Barton. With a total of 224 patents and applications, StarPharma is also the only company with a dendrimer in clinical trials. "As far as I know they are still out in front, nobody else is close to bringing its dendrimer along as far as they have," says Steven Rutt, IP attorney at Foley & Lardner in Washington, DC. But he still sees room to patent, stating "in an area like dendrimers, where there are so many things to tinker with, it allows you to come up with new improvements." Another dendrimer researcher, Harald Pielartzik, formerly of Bayer, agrees with Rutt: "When industry finds an application, then it's completely normal to license a technology, talk to each other, cooperate. I don't see that as a barrier." "
Vivien Marx Nature Biotechnology 26, 729 - 732 (2008)
|
| "Business watch SOURCE: PHARMAVISION Companies are racing to produce treatments that exploit RNA interference (RNAi), a natural process that silences gene expression in cells. PharmaVision, a biomedical consultancy based in Chichester, UK, estimates that the market for RNAi therapies could be worth more than US$2.9 billion by 2020. But no RNAi therapy has yet completed phase III clinical trials. With concern growing over the side effects of RNAi-based treatments, firms must now "conclusively prove the mechanism of action of their products", says PharmaVision consultant Cheryl Barton. For details of full article see: http://www.nature.com/news/2009/091202/full/462548a.html "
Ananyo Bhattacharya, 2 December 2009 | Nature 462, 548-549 (2009)
|
| "Nature Medicine volume 16 | number 7 | july 2010 Timing is everything “The market is demanding controlled release technology,” says Cheryl Barton, director of the Chichester, UK–based biomedical consultancy Pharmavision. Shenotes that patients like the convenience of once-a-day pills as opposed to having to remember to take multiple doses morning, noon and night. According to a 2009 Pharmavision report, medications using controlled release technology generate annual sales in excess of $20 billion. And although the majority of such sales currently derive from pill formulations, injectables are on the rise, Barton says. From a market research point of view, Pharmavision’s Barton sees increasing dialogue between companies that develop drugs and those that develop time-release technology. The chemical engineers behind these technologies are taking greater initiative in thinking up new applications. “They’re actually talking to the drug development guys much earlier,” she says. Proponents of this type of sustained release technology advocate that it extends both the drug’s effect and the patient’s life. In many parts of the world, price has proven to be another major deterrent to long-acting drugs. “There’s a price to be paid for the convenience of those products,” says Barton. This, she notes, has resulted in uneven adoption of time-release medications from country to country. “One of the biggest markets for this has been the US,” she explains, but European countries with nationalized health systems seem less keen to pay for such medications." For article visit http://www.nature.com/nm/journal/v16/n7/pdf/nm0710-737.pdf"
Roxanne Khamsi
|